Hello, you have come here looking for the meaning of the word
GLP-1. In DICTIOUS you will not only get to know all the dictionary meanings for the word
GLP-1, but we will also tell you about its etymology, its characteristics and you will know how to say
GLP-1 in singular and plural. Everything you need to know about the word
GLP-1 you have here. The definition of the word
GLP-1 will help you to be more precise and correct when speaking or writing your texts. Knowing the definition of
GLP-1, as well as those of other words, enriches your vocabulary and provides you with more and better linguistic resources.
English
Noun
GLP-1 (countable and uncountable, plural GLP-1s)
- (biochemistry) Initialism of glucagon-like peptide-1, an incretin (gastrointestinal hormone).
- (informal, countable) Ellipsis of GLP-1 RA (“glucagon-like peptide-1 receptor agonist”), a class of drugs used for the medication of diabetes and weight loss.
- Hyponym: semaglutide
2023 October 9, Tressie McMillan Cottom, “Ozempic Can’t Fix What Our Culture Has Broken”, in The New York Times, →ISSN:If GLP-1 drugs only treated diabetes and did not promote weight loss, they would still be medically groundbreaking.
2024 February 29, Edward Helmore, “Oprah Winfrey announces she is stepping down from WeightWatchers”, in The Guardian, →ISSN:An apparent conflict between WeightWatchers, which promotes a non-medical, points-based approach to food intake, and the talkshow host came in December when she told People magazine that she integrated GLP-1 drugs, brands that include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, into her existing “holistic approach” of “regular exercise and other lifestyle tweaks”.
2025 April 29, Tammy LaGorce, “How Ozempic Is Shaping Weddings”, in The New York Times, →ISSN:Some brides say explicitly that they are using GLP-1s, while for others, Ms. Yang, who said she uses Mounjaro herself, has her suspicions.
2025 May 10, “WeightWatchers blames diet drugs and social media for Chapter 11 bankruptcy”, in FT Weekend, page 13:Its lawyers said it could no longer service a $1.6bn debt load because of an “evolution in consumer preferences and the rapid rise of GLP-1s”, and it was seeking an aggregate valuation of $700mn.
2025 May 15, Jennifer Weiner, “WeightWatchers Got One Thing Very Right”, in The New York Times, →ISSN:Those days are gone. WeightWatchers and its commercial diet program peers have struggled to maintain market share in the era of GLP-1s, the class of drugs that includes Ozempic, Wegovy and Mounjaro, which give users a much higher chance of success.